These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28812020)

  • 1. Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
    Yang F; Li D; Di Y; Zhang Y; Zang Y; Ren J; Yan L; Zhou Z; Liu H; Xu Z
    Biomed Res Int; 2017; 2017():7450459. PubMed ID: 28812020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
    Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
    Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease.
    Lakhey M; Ghimire R; Shrestha R; Bhatta AD
    Kathmandu Univ Med J (KUMJ); 2010; 8(30):158-63. PubMed ID: 21209527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.
    Singh S; Singh R; Sharma PK; Singh UP; Rai SN; Chung LW; Cooper CR; Novakovic KR; Grizzle WE; Lillard JW
    Cancer Lett; 2009 Sep; 283(1):29-35. PubMed ID: 19375853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma.
    Işikay L; Yaman O ; Bozlu M; Müftüğlu YZ; Göğüş O
    Int Urol Nephrol; 1995; 27(6):757-61. PubMed ID: 8725043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal alkaline phosphatase: a marker for individual follow-up in patients with advanced prostatic cancer.
    Wechsel HW; Petri E; Bichler KH
    Urol Int; 1997; 58(2):80-3. PubMed ID: 9096267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
    Zhang HL; Qin XJ; Cao DL; Zhu Y; Yao XD; Zhang SL; Dai B; Ye DW
    Asian J Androl; 2013 Mar; 15(2):231-5. PubMed ID: 23377530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
    Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
    J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
    Tumminello FM; Badalamenti G; Incorvaia L; Fulfaro F; D'Amico C; Leto G
    Med Oncol; 2009; 26(1):10-5. PubMed ID: 18461289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate tissue and serum markers.
    Mazzucchelli R; Colanzi P; Pomante R; Muzzonigro G; Montironi R
    Adv Clin Path; 2000 Jul; 4(3):111-20. PubMed ID: 11080790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.